MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas

Inga Grünewald1, Marcel Trautmann1, Alina Busch2

  • 1Department of Pathology, University Hospital Muenster, Muenster, Germany.

Oncotarget
|September 24, 2016
PubMed

Insights

Salivary duct carcinoma (SDC) involves TP53 mutations and alterations in the p53 regulatory network. This study investigates MDM2, CDK4, and HMGA2 alterations in SDC, revealing new insights into tumorigenesis.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Salivary duct carcinoma (SDC) is an aggressive cancer with poor outcomes.
  • TP53 mutations are common in SDC, but other p53 regulatory network alterations are less understood.
  • Alterations in MDM2, CDK4, and HMGA2 at chromosomal region 12q13-15 are implicated in SDC pathogenesis.

Purpose of the Study:

  • To analyze TP53 mutations, MDM2/CDK4 amplifications, and HMGA2 rearrangements/amplifications in SDC.
  • To assess the protein expression of p53, MDM2, and CDK4 in SDC.
  • To investigate the role of 12q13-15 alterations in SDC tumorigenesis.

Main Methods:

  • Analysis of TP53 mutational status.
  • Genomic analysis for MDM2, CDK4 amplification, and HMGA2 rearrangement/amplification using techniques like FISH or array CGH.
  • Immunohistochemistry for p53, MDM2, and CDK4 protein expression.
  • Study included 51 SDC cases (de novo and ex pleomorphic adenoma).

Main Results:

  • TP53 mutations were found in 25 out of 51 cases.
  • MDM2 amplification occurred in 3 cases, CDK4 amplification in 2 cases.
  • HMGA2 rearrangements/amplifications were observed in conjunction with MDM2/CDK4 alterations.
  • Some MDM2/CDK4 amplifications were associated with TP53 mutations.

Conclusions:

  • Subgroups of SDC exhibit genomic amplifications of MDM2 and/or CDK4.
  • These amplifications can be associated with TP53 mutations and HMGA2 alterations.
  • Further research is needed to understand the prognostic and therapeutic implications of 12q13-15 alterations in SDC.